AstraZeneca has announced that it will withdraw its listing of American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares and the debt securities on the New York Stock Exchange next month.
The listing of the ADSs and the Debt Securities on Nasdaq is expected to cease on 30 January, and the ordinary shares and debt securities will commence trading on the NYSE from 2 February.
The ordinary shares will continue to be listed under the ticker symbol "AZN".
The Anglo-Swedish drugmaker said on Tuesday (20) that the direct listing at NYSE is a part of its shareholder approved plan to harmonise its share listing structure for global investors.
US investments
Like other drug majors, AstraZeneca is also ramping up US manufacturing as the Trump administration considers a 100 percent tariff on imported branded and patented medicines.
Although enforcement is delayed for companies investing in US manufacturing, the policy has already prompted fast-tracked projects.
AstraZeneca has secured multi-year tariff exemptions for the US market through pricing deals and commitments to the new TrumpRx.gov platform.
It will invest $50 billion in US manufacturing by 2030. The investment will fund a new drug substance facility in Virginia, its largest single-site global investment, alongside expansions in Maryland, Massachusetts, California, Indiana and Texas.
It has already started technology transfers and is managing inventory to minimise any tariff hit.
